2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide.

Abstract

This invention relates to compound of the formula (I): wherein: A is an alkylene group having 1 to 4 carbon atoms, said alkylene group being unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of a halogen atom, an alkyl group having 1 to 4 carbon atoms, a hydroxy-alkyl group having 1 to 4 carbon atoms and an alkoxy-alkyl group having 2 to 6 carbon atoms, wherein any 2 nonhalogen substituents can be taken together with the carbon atoms to which they are attached to form a 3 to 6-membered ring optionally containing at least one heteroatom selected from N, 0, and S; R1 is an isopropyl group or a cyclopentyl group; R2 is a hydrogen atom, a halogen atom or a hydroxy group; R3 is a carboxy group, a tetrazolyl group, a 5-oxo-1,2,4-oxadiazole-3-yl group or a 5oxo-1,2,4-thiadiazole-3-yl group; and m is the integer 1 or 2; composition containing such compound and the use of such compound in the treatment of a condition mediated by 5-HT4 receptor activity such as, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.